HC Wainwright set a $3.00 price objective on Lipocine (NASDAQ:LPCN) in a research report sent to investors on Friday, MarketBeat Ratings reports. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.
A number of other analysts have also recently issued reports on the company. Ladenburg Thalmann Financial Services reissued a buy rating and set a $11.00 target price on shares of Lipocine in a research note on Thursday. Canaccord Genuity reaffirmed a hold rating and set a $2.00 price target (down from $11.00) on shares of Lipocine in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. Lipocine has a consensus rating of Hold and a consensus target price of $13.50.
Lipocine (LPCN) traded down $0.16 during midday trading on Friday, reaching $1.71. The company had a trading volume of 1,580,000 shares, compared to its average volume of 622,569. Lipocine has a twelve month low of $1.67 and a twelve month high of $5.33. The company has a market cap of $36.25, a PE ratio of -1.78 and a beta of 0.11.
Several institutional investors and hedge funds have recently modified their holdings of LPCN. Goldman Sachs Group Inc. bought a new position in shares of Lipocine during the 2nd quarter worth approximately $300,000. Federated Investors Inc. PA grew its stake in shares of Lipocine by 9.2% during the 2nd quarter. Federated Investors Inc. PA now owns 88,083 shares of the specialty pharmaceutical company’s stock worth $354,000 after acquiring an additional 7,429 shares in the last quarter. P.A.W. Capital Corp bought a new position in shares of Lipocine during the 3rd quarter worth approximately $397,000. Ameriprise Financial Inc. grew its stake in shares of Lipocine by 18.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 155,600 shares of the specialty pharmaceutical company’s stock worth $626,000 after acquiring an additional 24,000 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Lipocine by 39.7% during the 2nd quarter. Vanguard Group Inc. now owns 546,027 shares of the specialty pharmaceutical company’s stock worth $2,195,000 after acquiring an additional 155,110 shares in the last quarter. 22.06% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Lipocine (LPCN) Given a $3.00 Price Target at HC Wainwright” was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.thestockobserver.com/2018/01/13/lipocine-lpcn-given-a-3-00-price-target-at-hc-wainwright.html.
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.